LifeStance Health Group (LFST)
(Delayed Data from NSDQ)
$5.04 USD
-0.06 (-1.18%)
Updated Jul 10, 2024 04:00 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LFST 5.04 -0.06(-1.18%)
Will LFST be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LFST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFST
Down -8.97% in 4 Weeks, Here's Why You Should You Buy the Dip in LifeStance Health (LFST)
LifeStance Health Group (LFST) Reports Q1 Loss, Tops Revenue Estimates
LFST: What are Zacks experts saying now?
Zacks Private Portfolio Services
RadNet (RDNT) Q1 Earnings and Revenues Surpass Estimates
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
LifeStance Health (LFST) Soars 6.6%: Is Further Upside Left in the Stock?
Other News for LFST
Mikra Applies to Health Canada for CELLF 2.0 NPN
Mikra Products to be Featured in Amazon Prime Days Promotion
Lifeist Appoints Andrea Judge CEO of Mikra Cellular Sciences
Lifeist Explores Legal Options Regarding Hedge Fund Settlement
Lifeist Wellness Reviews Response to SEC Settlement